Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation
Randomized study in people · 2022
- What was studied
- 90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.
- Main finding
- Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.
Sperm DNA fragmentation after course 1 · Median 10.23% (IQR 8.12–17.90) with Prostatilen AC. · Lower than placebo by the reported rank test. · p = 0.000022 between groups
Reported findings and study design
Double-blind, parallel, multicenter Phase IV study. Men received one 30 mg + 180 mg rectal suppository daily or matching placebo for 10 days. After a 21-day interval both arms received 10 days of active drug. DNA fragmentation was assessed using the TUNEL assay.
Population or model 90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Sperm DNA fragmentation after course 1 | Median 10.23% (IQR 8.12–17.90) with Prostatilen AC. | Lower than placebo by the reported rank test. · p = 0.000022 between groups |
| Sperm DNA fragmentation after course 2 | Median 6.91% (IQR 4.91–11.30) after two active courses. | 14.56% (IQR 13.96–16.50) after placebo then an active course. · p = 0.00004 between groups |
| Seminal plasma antiradical activity | Reported between-group difference of +6.72% after course 1 and +23.7% after course 2. | p = 0.02 and p = 0.0049, respectively |
| Adverse events and PSA | 12 reports of tenesmus or anal burning in 10 participants, with no treatment withdrawal or dosing change. The authors reported stable prostate-specific antigen. |
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- Both groups received active treatment in the second course. That comparison estimates the difference between two courses and one course.
- The trial evaluates a prostate extract and zinc-complex formulation, with no extract-only or zinc-only comparator. It measured semen markers and leaves pregnancy and live birth outcomes unanswered.
Source details
Original journal report
Original journal PDF, recruitment, treatment sequence, adverse events and Figures 1–3.
Sources checked
Citation
Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology
Published
I. B. Yakovlev, S. V. Teplykh, M. A. Rybalov, S. Yu. Borovets, V. B. Vasilyuk, M. V. Faraponova, A. A. Krasnov, S. V. Petlenko, V. A. Apryatina. Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation Experimental and Clinical Pharmacology. 2022;85(2):11–15.
Study source ↗ · DOI 10.30906/0869-2092-2022-85-2-11-15 · Bibliography entry · Link to this summary